Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Net formulary alternatives & Prior Auth | O…
    Ask Trek AI about this page
    CurrentHealth NetPolicy N/A

    Formulary alternatives and restrictions for non-covered drugs

    Customize your policy alerts

    Sign up for all Health Net policy alerts

    Know when Health Net releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists common drugs that are not covered on the Health Net formulary and suggests covered alternative drugs, plus formulary restrictions such as prior authorization (PA) and quantity limits (QL); it is intended for providers and pharmacists applying the Health Net formulary.

    Policy Summary
    PayerHealth Net
    PolicyFormulary alternatives and restrictions for non-covered drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionCheck the Plan formulary and submit prior authorization with supporting documentation when a non-formulary drug requires PA.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    40,000+drugs covered by Health Net
    May 1, 2025document currency date
    multiple

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    formulary restrictions shown

    Formulary Alternatives and Coverage Rules

    Formulary alternatives

    Formulary guidance and coverage stance for listed non-formulary drugs and their suggested alternatives

    Formulary alternative suggested: For each non-formulary drug listed, a covered alternative or alternatives are provided (examples: NovoLog® alternatives: none listed on formulary; Insulin Glargine‑yfgn alternatives: Semglee®, Lantus®; Victoza® alternatives: Mounjaro®, Ozempic®; Advair Diskus® alternatives: Fluticasone‑Salmeterol Diskus**, Breyna®, Breo Ellipta®, Advair HFA®).

    Providers should consider the suggested alternatives; the list is not exhaustive and alternatives are suggestions only.

    Prior authorization and quantity limits

    Restrictions applied to certain drugs

    PA or QL applied: Specific non‑formulary drugs have restrictions noted (examples: Repatha® — PA; Forteo® — PA and QL; Procrit® — PA; Xeljanz® / Xeljanz XR® — PA and QL; selected inhalers and other agents noted with QL).

    Check the Plan's drug list for exact prior authorization criteria and quantity limits; failure to obtain required PA may result in denial.

    This document is a formulary crosswalk that lists common brand drugs that are not covered on the Health Net formulary and provides suggested, covered alternatives where available. The list also indicates where formulary restrictions apply, including prior authorization (PA) and quantity limits (QL). It is intended to guide prescribing and pharmacy decisions but does not guarantee coverage of a non‑formulary drug without appropriate authorization and documentation.

    Providers and pharmacists should use the suggested alternatives to select formulary medications when clinically appropriate, or to prepare supporting documentation if a non‑formulary agent is clinically necessary. For specific PA rules, QL amounts, or to confirm current coverage status, refer to the Plan drug list and PA criteria, since the formulary and restrictions may change.

    Required Actions for Prescribers and Pharmacists

    Prior Authorization

    Obtain prior authorization for listed non‑formulary drugs

    Certain non-formulary drugs listed in this crosswalk require prior authorization (PA) before the Plan will cover them. Examples called out in the document include Repatha®, Forteo®, Procrit® and Xeljanz® (and Xeljanz XR®). When PA is required, the provider must submit the Plan’s prior authorization request and supporting documentation to obtain coverage.

    • Repatha® — Formulary restriction: PA (see list)
    • Forteo® — Formulary restriction: PA and QL (PA required for coverage)
    • Procrit® — Formulary restriction: PA
    • Xeljanz® / Xeljanz XR® — Formulary restrictions: PA and QL
    Step Therapy

    Preferred formulary alternatives imply step therapy

    The table lists covered alternatives for many non‑formulary products, indicating the Plan prefers trial of formulary alternatives before the non‑formulary agent (implied step therapy). Providers should consider prescribing the listed preferred alternatives (e.g., Semglee® or Lantus® for Insulin Glargine‑yfgn; Mounjaro® or Ozempic® for Victoza®) prior to requesting coverage for the non‑formulary brand.

    Document Purpose and Scope

    Background: The crosswalk maps non‑formulary brand products to preferred formulary alternatives across common therapeutic areas (examples from the list include insulin products mapped to Semglee® or Lantus®; GLP‑1 agonists such as Victoza® mapped to Mounjaro® or Ozempic®; and inhaled controller products such as Advair Diskus® mapped to fluticasone‑salmeterol products, Breyna® or Breo Ellipta®).

    The document also highlights formulary restrictions applied to certain non‑formulary drugs — for example, Repatha®, Forteo®, Procrit®, and Xeljanz®/Xeljanz XR® are noted with PA, and some entries (for example, Advair Diskus®, Forteo®, Xeljanz®) carry QL designations. These mappings and restriction flags are intended to help prescribers choose covered alternatives or assemble the necessary PA documentation.

    Note: Alternative drugs are suggestions only and may not be appropriate for every patient or condition. The information is current as of May 1, 2025; providers must check the Plan drug list for the most up‑to‑date coverage and specific PA/QL requirements.

    Key Terms

    Prior Authorization (PA)
    DefinitionPrior authorization (PA) indicates prior authorization is required before the Plan will cover the drug.
    When appliedPA is noted for specific non‑formulary drugs (examples: Repatha®, Forteo®, Procrit®, Xeljanz®).
    Provider actionA PA request and supporting documentation must be submitted to the Plan for drugs listed with PA to be considered for coverage.
    Quantity Limit (QL)
    DefinitionQuantity limit (QL) indicates quantity limit restrictions are applied to the formulary drug.
    ExamplesQL is applied to several inhaled therapies and other agents (examples in this document: Advair Diskus®, Symbicort®, Dulera®, Pulmicort Flexhaler®, Levalbuterol HFA, Spiriva Handihaler®).

    Preferred Alternatives and Step Therapy Implications

    Non‑formulary drugPreferred formulary alternative(s)Notes (PA / QL)
    NovoLog®None listed on formularyFormulary restrictions noted for NovoLog® (see drug list)
    NovoLog mix 70/30®None listed on formularyFormulary restrictions noted for NovoLog mix 70/30®
    Insulin Glargine‑yfgnSemglee®; Lantus® (alternatives also include Basaglar KwikPen®, Levemir®)Alternatives listed on formulary
    Victoza®Mounjaro®; Ozempic®Formulary alternatives listed
    Advair Diskus® / Wixela Inhub®Fluticasone‑Salmeterol Diskus**; Breyna®; Breo Ellipta®; Advair HFA®QL indicated for Advair Diskus® and Wixela Inhub®
    Symbicort®Breyna**; Fluticasone‑Salmeterol Diskus; Breo Ellipta; Advair HFAQL indicated for Symbicort®
    Dulera®Breyna; Fluticasone‑Salmeterol Diskus; Breo Ellipta; Advair HFAQL indicated for Dulera®
    Pulmicort Flexhaler® / Flovent®Arnuity Ellipta®QL indicated for Pulmicort Flexhaler® and Flovent®
    Levalbuterol HFAAlbuterol HFA; Ventolin HFA®QL indicated for Levalbuterol HFA
    Gemtesa®Fesoterodine ER; or Oxybutynin IR (listed variably)Gemtesa® noted with QL in some entries
    Repatha®Praluent®PA required for Repatha®

    Quantity Limit Notices

    Advair Diskus® and QL‑noted Products
    Drugs referencedAdvair Diskus® and other inhaled products in this table are noted with quantity limits.
    Specific limitsSee the Plan's formulary (drug list) for the exact quantity limit (QL) applied to Advair Diskus® and each listed product.
    Formulary alternativesCovered alternatives are listed (examples: Fluticasone‑Salmeterol Diskus**, Breyna®, Breo Ellipta®, Advair HFA®).
    Forteo® (QL noted)
    DrugForteo® (teriparatide)
    Formulary statusCovered alternative listed: Teriparatide 620mcg/2.48ml; Prolia® also shown as alternative in the table.

    Biosimilar Alternatives

    Billing Rule

    Lantus® and Semglee® listed as alternatives for insulin glargine‑yfgn

    For insulin glargine products the crosswalk lists Lantus® and the biosimilar Semglee® (insulin glargine‑yfgn) as covered alternatives where applicable; providers should consider these listed alternatives when selecting therapy.

    • Insulin Glargine‑yfgn — listed formulary alternatives include Semglee® and Lantus®.
    Policy Summary
    PayerHealth Net
    PolicyFormulary alternatives and restrictions for non-covered drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionCheck the Plan formulary and submit prior authorization with supporting documentation when a non-formulary drug requires PA.
    SourceLink
    On This Page
    Formulary Alternatives and Coverage RulesRequired Actions for Prescribers and PharmacistsDocument Purpose and ScopeKey TermsPreferred Alternatives and Step Therapy ImplicationsQuantity Limit NoticesBiosimilar Alternatives
    • Insulin Glargine‑yfgn — preferred alternatives: Semglee®, Lantus®
    • Victoza® — preferred alternatives: Mounjaro®, Ozempic®
    • Advair Diskus® — formulary alternatives listed (Fluticasone‑Salmeterol Diskus**, Breyna®, Breo Ellipta®, Advair HFA®)
    Documentation Required

    Verify formulary coverage and document medical necessity

    Check the Plan’s current formulary (drug list) for coverage status and any PA or quantity limit (QL) restrictions before prescribing. For PA requests, include documentation that supports medical necessity to substantiate the request.

    • Use the Plan’s drug list for a comprehensive, up‑to‑date listing of covered drugs and restrictions
    • Include clinical documentation when submitting PA to demonstrate medical necessity
    Denial Risk

    Risk of denial if PA or quantity limits not followed

    Failure to obtain required prior authorization or to adhere to noted quantity limits may result in claim denial. The document explicitly warns that requests for non‑formulary drugs may be subject to PA or QL and that failure to obtain PA when required risks denial.

    • Non‑formulary requests subject to PA/QL (examples: Forteo® and Xeljanz® have PA and QL)
    • Claims for drugs with PA/QL may be denied if PA is not obtained or QL exceeded
    Check listProviders should check the Plan's formulary (drug list) for exact QL values for each product, since limits are specified on the drug list.
    Restrictions
    Forteo® is noted with Prior Authorization (PA) and Quantity Limit (QL).
    Xeljanz® / Xeljanz XR® (QL noted)
    DrugsXeljanz® and Xeljanz XR®
    Formulary alternativesAlternatives listed include multiple biologics/small molecules (examples shown: Cyltezo® low concentration, Humira®, Enbrel®, Rinvoq®, Skyrizi®, Stelara®, Cosentyx®, Tremfya®, Otezla®, Actemra®).
    RestrictionsXeljanz® and Xeljanz XR® are noted with Prior Authorization (PA) and Quantity Limit (QL).